Table 2.
Representative in vivo demonstrations on subcutaneous xenografted tumor models (2010–2018).
| Ref | Years | Tumor Types | Tumor Size | Survival Rate | Tumor Diagnostics |
|---|---|---|---|---|---|
| [53] | 2010 | Glioblastoma | Decreased | N/A | Bioluminescence imaging |
| [49] | 2010 | Bladder cancer | Decreased | Increased | Tissue size measurement |
| [54] | 2011 | Glioblastoma | Decreased | Increased | Bioluminescence imaging |
| [55] | 2012 | Pancreatic carcinoma | Decreased | N/A | Bioluminescence imaging |
| [56] | 2012 | Glioblastoma | Decreased | N/A | Bioluminescence imaging |
| [57] | 2013 | Neuroblastoma | Decreased | Increased | Tissue size measurement |
| [58] | 2014 | Melanoma | Decreased | N/A | Tissue size measurement |
| [59] | 2014 | Head and neck cancer | Decreased | N/A | Tissue size measurement |
| [48] | 2015 | Melanoma | Decreased | Increased | Tissue size measurement |
| [60] | 2015 | Endometrioid adenocarcinoma | Decreased | N/A | Tissue size measurement |
| [61] | 2016 | Glioblastoma | Decreased | N/A | Tissue size measurement |
| [62] | 2016 | Breast cancer | Decreased | N/A | Tissue size measurement |
| [50] | 2017 | Melanoma | Decreased | N/A | Bioluminescence imaging |
| [63] | 2018 | Colorectal tumor | Decreased | N/A | Tissue size measurement |